Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering? (Journal article)

Milionis, H. J./ Gazi, I. F./ Filippatos, T. D./ Tzovaras, V./ Chasiotis, G./ Goudevenos, J./ Seferiadis, K./ Elisaf, M. S.

The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n = 55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,C-Reactive Protein/analysis,Cholesterol, HDL/blood,Cholesterol, LDL/blood,Female,Fluorobenzenes/administration & dosage/adverse effects/*therapeutic use,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse,effects/*therapeutic use,Hyperlipidemias/*drug therapy,Kidney/drug effects,Male,Middle Aged,Pyrimidines/administration & dosage/adverse effects/*therapeutic use,Sulfonamides/administration & dosage/adverse effects/*therapeutic use,Treatment Outcome
ISSN: 0003-3197
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Milionis-2005-Starting with rosuva.pdf84.28 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.